Is the Patient Health Questionnaire-9 (PHQ-9) suitable for a 13-year-old?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PHQ-9 Use in 13-Year-Olds

Yes, the PHQ-9 is suitable and validated for use in 13-year-olds, with universal depression screening recommended starting at age 12 years. 1, 2

Evidence Supporting PHQ-9 Use at Age 13

The PHQ-9 has been specifically validated in adolescent populations aged 13-17 years, demonstrating strong psychometric properties:

  • Sensitivity of 89.5% and specificity of 77.5% at a cutoff score of 11 for detecting major depressive disorder in adolescents 1, 3
  • The validation study included 442 youth aged 13-17 years, confirming the tool performs well in this exact age range 3
  • Multiple studies have confirmed the PHQ-9's validity specifically in adolescents aged 13-16 years in pediatric care settings 4

Guideline Recommendations for Starting Age

Universal depression screening should begin at age 12 years and continue through age 18 years according to both the USPSTF and American Academy of Pediatrics GLAD-PC guidelines 1, 2. This recommendation is based on:

  • Validated screening tools available for this age group 5, 1
  • Evidence-based treatments (SSRIs and psychotherapy) proven effective in adolescents aged 12-14 years and older 1
  • Mean age of onset for major depressive disorder is approximately 14-15 years, making age 12 an appropriate starting point 1

Optimal Cutoff Score for Adolescents

Use a cutoff score of 11 or higher for adolescents, which is higher than the adult cutoff of 10 1, 3. This cutoff maximizes sensitivity (89.5%) without loss of specificity (77.5%) in the adolescent population 3.

Scoring Algorithm and Management

Apply the dimensional scoring algorithm (sum of all 9 items, range 0-27) rather than the categorical algorithm:

  • PHQ-9 score 1-7 (none/mild): Provide education about depression, ensure adequate coping skills, consider reassessment at future visits 1
  • PHQ-9 score 8-14 (moderate): Evaluate pertinent history and risk factors, consider referral to psychology/psychiatry for diagnostic evaluation 1
  • PHQ-9 score 15-27 (severe): Make immediate referral to psychology and/or psychiatry, assess for risk of harm to self or others 1

The categorical algorithm should not be used in adolescents due to unacceptably low sensitivity of only 52.5% 4.

Critical Implementation Considerations

Always pay particular attention to item 9 (thoughts of self-harm), which requires immediate referral for patients with specific plans or intent for self-harm 5, 1, 2.

Consider using a two-stage approach:

  • Start with PHQ-2 (cutoff ≥3) as initial screening, which has sensitivity of 73.7% and specificity of 75.2% 1
  • If PHQ-2 is positive, administer the full PHQ-9 5, 1, 6
  • However, be aware this approach may miss some cases of suicidality that would be detected by administering the full PHQ-9 initially 1

Essential Pitfall to Avoid

Never screen without having a clear protocol for managing positive screens. Screening alone without intervention does not improve outcomes and may cause harm 5, 1, 2. The evidence shows that adolescents who receive evidence-based treatment after screening have significantly better outcomes than those who are only screened 5.

Alternative Considerations

While the standard PHQ-9 is validated for 13-year-olds, the PHQ-9 Modified for Teens may be more appropriate when screening adolescents, as it uses language better suited to this population 1, 7. The modified version has demonstrated good internal consistency (Cronbach's α = 0.879) in treatment-seeking depressed adolescents aged 13-18 years 7.

References

Guideline

Depression Screening and Management Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tamizaje de Depresión con PHQ-9

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.